Entera Bio Ltd. EV/Operating CF

EV/Operating CF of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Operating CF growth rates and interactive chart. A valuation metric that measures the enterprise value of a company compared to its operating cash flow. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low EV/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current EV/Operating CF of Entera Bio Ltd. is -1.23 (as of December 30, 2019)
  • EV/Operating CF for the quarter ending June 29, 2020 was -2.16 (a -12.99% decrease compared to previous quarter)
  • Year-over-year quarterly EV/Operating CF decreased by -28.14%
  • Annual EV/Operating CF for 2019 was -1.23 (a -70.15% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Operating CF of Entera Bio Ltd.

Most recent EV/Operating CFof ENTX including historical data for past 10 years.

Interactive Chart of EV/Operating CF of Entera Bio Ltd.

Entera Bio Ltd. EV/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -2.16 -2.48
2019 -1.23 -3.01 -3.77 -1.23
2018 -4.11 -4.11

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.